Martin Citron

Physiology · 2010

A researcher in the Science corpus: 1 paper; trusts 6 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Physiology — 27 citations into it; #1,978 of 2,276 by trust here, #2,004 by citations
• Pharmacology — 10 citations into it; #955 of 1,112 by trust here, #862 by citations
• Molecular Biology — 8 citations into it
• Computational Theory and Mathematics — 6 citations into it; #11,733 of 12,182 by trust here, #8,294 by citations
• Genetics — 6 citations into it
• Neurology — 5 citations into it

Whom Martin Citron trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. G. Bu
2. Lars Bertram
3. C. Frederickson
4. D. Selkoe
5. T. Wyss‐Coray
6. D. Holtzman

Who trusts Martin Citron overall

1. Kasper P. Kepp
2. Johannes Gräff

Papers from Martin Citron's perspective

Ordered by how strongly the researchers Martin Citron trusts endorse each paper. Same corpus, a different order for every researcher.

1. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses (Nature Reviews Neuroscience)
2. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes (Nature Genetics)
3. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function (Science)
4. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease (Nature)
5. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. (Proceedings of the National Academy of Sciences of the United States of America)
6. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy (Nature Reviews Neuroscience)
7. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease (Proceedings of the National Academy of Sciences of the United States of America)
8. Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* (Journal of Biological Chemistry)
9. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
10. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity (Nature)

Their papers

• Alzheimer's disease: strategies for disease modification (2010) — 1,060 citations